Anthracycline and anthraquinone anticancer agents: current status and recent developments
about
Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cellsMultiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cellsExperiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran.HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics.Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.Molecular dynamics of anthraquinone DNA intercalators with polyethylene glycol side chains.Polycyclic aromatic compounds as anticancer agents: Evaluation of synthesis and in vitro cytotoxicityAssociation of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer PatientsCellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-l-malic acid)The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicinATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistanceOver-expression of a modified bifunctional apoptosis regulator protects against cardiac injury and doxorubicin-induced cardiotoxicity in transgenic miceExcessive formation of hydroxyl radicals and aldehydic lipid peroxidation products in cultured skin fibroblasts from patients with complex I deficiency.DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: a review.Poly(malic acid) bearing Doxorubicin and N-Acetyl Galactosamine as a site-specific prodrug for targeting hepatocellular carcinoma.Anthraquinones As Pharmacological Tools and Drugs.Catalytic asymmetric reactions and synthesis of quinones.Acetylamine derivative of diospyrin, a plant-derived binaphthylquinonoid, inhibits human colon cancer growth in Nod-Scid mice.3-Bromo-1-hydroxy-9,10-anthraquinone (BHAQ) inhibits growth and migration of the human breast cancer cell lines MCF-7 and MDA-MB231.Rhodomycin analogues from Streptomyces purpurascens: isolation, characterization and biological activities.Protective effect of plaunotol against doxorubicin-induced renal cell death.Effects of new quinizarin derivatives on both HCV NS5B RNA polymerase and HIV-1 reverse transcriptase associated ribonuclease H activities.Hexane/ethanol extract of Glycyrrhiza uralensis licorice suppresses doxorubicin-induced apoptosis in H9c2 rat cardiac myoblasts.Schiff base derived from thiosemicarbazone and anthracene showed high potential in overcoming multidrug resistance in vitro with low drug resistance index.Subchronic toxicity, immunoregulation and anti-breast tumor effect of Nordamnacantal, an anthraquinone extracted from the stems of Morinda citrifolia L.(Biphenyl-2-alkyne) derivatives as common precursors for the synthesis of 9-iodo-10-organochalcogen-phenanthrenes and 9-organochalcogen-phenanthrenes.New doxorubicin nanoparticles engineered from calcium-crosslinked carbomer and a microemulsion precursor.Combinatorial Cytotoxic Effects of Damnacanthal and Doxorubicin against Human Breast Cancer MCF-7 Cells in Vitro.
P2860
Q25257791-3F5A602D-EBFB-4441-A52A-9FAFD7314DCAQ28577227-0327AD25-5757-42DF-928E-4808C5AB8B8CQ30729687-2103745D-974F-48FD-A19E-FBC77A036C7DQ30979368-0A421CD1-125D-40A1-B544-F58B124D7E80Q33958482-10780907-4ABE-4F7C-89A2-2E0313D4E15DQ34146939-2B32531E-B65A-4B37-9766-D3BC5A2F0399Q35995460-6870A128-04E7-4D20-97CA-441B7405CB2DQ36236476-926FD95B-4581-474A-BE93-B1A74906CCF4Q36321843-E0D1F967-B9EA-484B-B209-B437F272AE16Q36564944-6A4E45C2-71C1-4C81-B019-1D6BAFE7D961Q36838262-BEF53486-0CE3-4D16-85D1-868EADD48C65Q37090521-07E5AF1A-3217-43AA-AEB6-2A23E46EF841Q37368652-E53D3C72-EE60-4E5E-9D6F-3425D12E1919Q37665271-1146C6A9-4B50-4824-9713-454E5C999FA8Q38038803-DCF5B951-3B17-4C37-956F-21DBF233F9A9Q38709628-B5CFDDC3-FFF7-454D-90D0-83E98F3314F5Q38816745-61E51B4C-D457-47BD-A204-00DC1C06213DQ38874469-96E77E36-1502-4333-8B0A-85926D5FF2A3Q38952634-56C34948-8C35-4CB9-975D-E5DDCA1C9CC9Q39103673-D203ABF6-3445-4AD7-B644-C0D6B780C0B0Q39143247-2F553CA6-D831-40B0-A079-C9B2C38BF05DQ39321425-E8AFA716-D30C-43C5-92D8-8B19DDC658EDQ39456904-FFB657F6-1249-47A3-B3C3-A090A4595A7CQ39930192-92FD75D6-8DF3-4641-9742-C2CD7377EE62Q41282935-1722C5CB-79E6-4BE7-9998-8EF6076372BAQ48157106-8F1F7258-E0AA-4C7A-8A87-B1A2E9292FEFQ48295325-9CB58242-D9F5-4557-8B36-6225A942D1A8Q51158697-20A5F5D9-7CC2-4BE8-A4CA-8EC6029F36CAQ51484741-6B5D4FF9-5C45-4D6F-AE4C-AA01D0329713
P2860
Anthracycline and anthraquinone anticancer agents: current status and recent developments
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@ast
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@en
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@nl
type
label
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@ast
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@en
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@nl
prefLabel
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@ast
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@en
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@nl
P1476
Anthracycline and anthraquinone anticancer agents: current status and recent developments
@en
P2093
P304
P356
10.1016/0163-7258(93)90006-Y
P407
P577
1993-11-01T00:00:00Z